Abstract
A body of in vitro evidence suggests that use of granulocyte-macrophage colony-stimulating factor (GM-CSF) might increase the in vivo sensitivity of leukemic myeloblasts to daunorubicin-cytosine arabinoside (ara-C) chemotherapy [1–4]. If so, administration of GM-CSF prior to and during administration of daunorubicin/ara-C might overcome the resistance to therapy that is characteristic of acute myeloid leukemia (AML). This resistance is most obvious in patients with abnormalities of chromosomes 5, 7, (−5, −7, 5q-, 7q-) who frequently fail even to enter initial complete remission (CR), but it is also a major problem in patients with other aneuploidies (except INV(16), t (15; 17), or t (8; 21)), or with a normal karyotype or insufficient metaphases for analysis [5].While the majority of these patients enter CR, their remissions rarely last more than 2 years.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cannistra SA, Groshek P, Griffin JD (1989) Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis of chronic myeloid leukemia. Leukemia 3: 328–334
Hiddemann W, Kiehl M, Schleyer E, Woermann B, Zuehlsdorf M, Buechner T (1989) Stimulating effect of GM-CSF and IL-3 on the metabolism and cytotoxic activity of cytosine arabinoside in leukemia blasts from patients with acute myeloid leukemia. Blood 74 (Suppl 1): 230a
Santini V, Noater K, Delwel R, Loewenberg B (1990) Susceptibility of acute myeloid leukemia cells from clinically resistant and sensi tive patient to daunomycin: assessment in vitro after stimulation with colony stimulating factors. Leuk Res 14: 377–380
Tafuri A, Andreeff M (1990) Kinetic rationale for cytokine-induced recruitment of myelo blastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 4: 826–835
Keating M, Cork A, Broach Y, Smith T, Walters R, McCredie K, Trujillo J, Freireich E (1987) Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res: 119–133
Cassileth PA, Harrington DP, Hines JD, Oken MM, Maza JJ, McGlave P, O’Connell MJ (1988) Maintenance chemotherapy prolongs remission duration in adult acute none lymphocytic leukemia. J Clin Oncol 6: 583–587
Keating M, Smith T, Kantarjian H, Cork A, Walters R, Trujillo J, McCredie K, Gehan E, Freireich E (1988) Cytogenetic pattern in acute myelogenous leukemia: a major repro ducible determinant of outcome. Leukemia 2: 403–412
Estey E, Smith T, Keating M, McCredie K, Gehan E, Freireich E (1989) Prediction of survival during induction therapy in patients with newly diagnosed acute myelogenous leukemia. Leukemia 3: 257–263
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Estey, E. et al. (1992). Use of Granulocyte-Macrophage Colony-Stimulating Factor Prior to Chemotherapy of Newly Diagnosed AML. In: Hiddemann, W., Büchner, T., Wörmann, B., Plunkett, W., Keating, M., Andreeff, M. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76591-9_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-76591-9_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53949-0
Online ISBN: 978-3-642-76591-9
eBook Packages: Springer Book Archive